No supplier or customer ties in BMEA's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Nothing on the wire mentions BMEA yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How BMEA has moved on past release days vs its typical ±4.4% day, and how often it closed up. Computed from daily closes — not a forecast.